Efficacy of IMRT Combined with Capecitabine Concurrent Chemotherapy and High Intensity Focused Ultrasound for Elderly Patients with Non-operatable Pancreatic Cancer
-
摘要:目的
探讨调强放疗（intensity modulated radiotherapy, IMRT）联合口服卡培他滨同步化疗及高强度聚焦超声（high intensity focused ultrasound, HIFU）治疗非手术老年胰腺癌患者的疗效及不良反应。
方法患者60例随机分为对照组和观察组，各30例。对照组行IMRT联合口服卡培他滨同步化疗，于放疗第1天开始给予卡培他滨800~1 000 mg/m2早晚饭后各口服一次，连续用药14天，休息7天行下一周期化疗，放疗结束后巩固化疗2~4周期。观察组行IMRT联合口服卡培他滨同步化疗及HIFU治疗，化疗方案同对照组，HIFU于放疗第1天开始，5次/周，连用4~6周。
结果对照组和观察组治疗前后疼痛评分比较差异有统计学意义（P=0.001, P < 0.0001）；两组间治疗前后疼痛减轻程度比较，差异有统计学意义（P=0.0162）。对照组和观察组的近期疗效组间比较，差异有统计学意义（Z=-2.159，P=0.031）。对照组和观察组在总生存率、无进展生存率、骨髓抑制、急性放射性肝损伤、急性放射性胃肠道损伤及急性放射性肾脏损伤不良反应发生率以及两组失败模式等方面比较，差异无统计学意义（P>0.05）。
结论IMRT联合卡培他滨同步化疗及HIFU治疗老年非手术胰腺癌可缓解患者疼痛，提高生活质量，近期疗效确切，但未延长患者长期生存。
Abstract:ObjectiveTo explore the clinical efficacy and toxicity of intensity modulated radiotherapy (IMRT) combined with oral capecitabine concurrent chemotherapy and HIFU for elderly patients with nonoperatable pancreatic cancer.
MethodsTotal 60 elderly patients with non-operatable pancreatic cancer were randomly divided into two group, 30 patients in control group received concurrent radiochemotherapy (intensity modulated radiation therapy (IMRT) with 6 MV X-ray and concurrently oral capecitabine (800-1 000 mg/m2, bid, d1-14, 21 days/cycle, concurrent chemotherapy for two cycles, consolidate chemotherapy for 2-4cycles)), and 30 patients in observation group received same concurrent radiochemotherapy and HIFU carried out concurrently with IMRT (5 days/week, 4-6 weeks).
ResultsThere was significant difference of pain relief score in both control and observation group before and after treatment (P=0.001, P < 0.0001); the degree of pain releif in the observation group was more than that in the control group (P=0.0162). The difference of the short-term effects between two groups was statistical (Z=-2.159, P=0.031). The over survival, progression-free survival, failure patterns and adverse effects, such as myelosuppression, radiation-induced liver disease, radiationinduced gastrointestinal disease and radiation-induced kidney disease, were not statistically different between two groups (P>0.05).
ConclusionIMRT combined with capecitabine concurrent chemotherapy and HIFU for elderly patients with non-operatable pancreatic cancer are safe and effective in relieving pain and improving the quality of life, but there isn't advantage in longer overall survival or longer progression-free survival.
-
Key words:
- Pancreatic cancer /
- IMRT /
- HIFU /
- Capecitabine
-
-
![]()
图 1 两组胰腺癌患者总生存率的比较
Figure 1 Comparison of 1-, 2-year overall survival rates between two groups in pancreatic cancer patients
![]()
图 2 两组胰腺癌患者进展生存率的比较
Figure 2 Comparison of 1-year progression-free survival rate between two groups in pancreatic cancer patients
表 2 两组胰腺癌患者近期疗效比较(n(%))
Table 2 Comparison of short-term effects between two groups in pancreatic cancer patients (n(%))
下载: 导出CSV
表 3 两组胰腺癌患者不良反应比较(n(%))
Table 3 Comparison of side effects between two groups in pancreatic cancer patents (n(%))
下载: 导出CSV
-
[1] Herman JM, Chang DT, Goodman KA, et al. Phase 2 multi-institutional trial evaluating gemcitabine and stereotacticbody radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinoma[J]. Cancer, 2015, 121(7): 1128-37. doi: 10.1002/cncr.v121.7
[2] 赵洪.胰腺癌的局部微无创治疗-高强度聚焦超声[J].上海医药, 2014, 35(8): 8-11. http://www.cnki.com.cn/Article/CJFDTOTAL-SYIY201408006.htm Zhao H. Non-invasive technology in treatment of pancreatic cancer: high intensity focused ultrasound therapy[J]. Shanghai Yi Yao, 2014, 35(8): 8-11. http://www.cnki.com.cn/Article/CJFDTOTAL-SYIY201408006.htm
[3] Wang Z, Ren ZG, Ma NY, et al. Intensity modulated radiotherapy for locally advanced and metastatic pancreatic cancer: a mono-institutional retrospective analysis[J]. Radiat Oncol, 2015, 10: 14. doi: 10.1186/s13014-014-0312-5
[4] 李泽朝, 周勇, 罗诗樵.胰腺癌肝转移患者多学科综合治疗临床分析[J].肿瘤防治研究, 2015, 42(2): 154-8. http://www.zlfzyj.com/CN/abstract/abstract8420.shtml Li ZC, Zhou Y, Luo SQ. Clinical Analysis of Multimodality Treatments for Pancreatic Cancer Patients with Liver Metastases[J]. Zhong Liu Fang Zhi Yan Jiu, 2015, 42(2): 154-8. http://www.zlfzyj.com/CN/abstract/abstract8420.shtml
[5] Cascinu S. Locally advanced versus metastatic pancreatic cancer: two different diseases with two different treatment approaches?[J]. Chin Clin Oncol, 2013, 2(3): 26. https://www.ncbi.nlm.nih.gov/pubmed/25841682
[6] Mukherjee S, Hurt CN, Bridgewater J, et al. Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomised, phase 2 trial[J]. Lancet Oncol, 2013, 14(4): 317-26. doi: 10.1016/S1470-2045(13)70021-4
[7] 时圣彬, 马廷行, 唐晓勇, 等.卡培他滨联合沙利度胺二线治疗晚期胰腺癌的疗效观察[J].中华肿瘤杂志, 2013, 35(4): 301-4. http://d.wanfangdata.com.cn/Periodical/zhzl201304013 Shi SB, Ma TH, Tang XY, et al. Effect of second-line treatment with capecitabine and thalidomide in patients with advanced pancreatic cancer[J]. Zhonghua Zhong Liu Za Zhi, 2013, 35(4): 301-4. http://d.wanfangdata.com.cn/Periodical/zhzl201304013
[8] Zhou Y. High-intensity focused ultrasound treatment for advanced pancreatic cancer[J]. Gastroenterol Res Pract, 2014: 205325. https://www.hindawi.com/journals/grp/2014/205325/
[9] Wang K, Chen Z, Meng Z, et al. Analgesic effect of high intensity focused ultrasound therapy for unresectable pancreatic cancer[J]. Int J Hyperthermia, 2011, 27(2): 101-7. doi: 10.3109/02656736.2010.525588
[10] Zhao H, Yang G, Wang D, et al. Concurrent gemcitabine and high-intensity focused ultrasound therapy in patients with locally advanced pancreatic cancer[J]. Anticancer Drugs, 2010, 21(4): 447-52. doi: 10.1097/CAD.0b013e32833641a7
[11] Keane MG, Bramis K, Pereira SP, et al. Systematic review of novel ablative methods in locally advanced pancreatic cancer[J]. World J Gastroenterol, 2014, 20(9): 2267-78. doi: 10.3748/wjg.v20.i9.2267
[12] Hammel P, Huguet F, Van Laethem JL, et al. Comparison of chemoradiotherapy (CRT) and chemotherapy (CT) in patients with locally advanced pancreatic cancer (LAPC) controlled after 4 months of gemcitabine with or without erlotinib: Final results of the international phase III LAP 07 study[J]. Pancreatology, 2013, 13(3): S89. http://meetinglibrary.asco.org/content/82889
[13] Li D, Kang J, Golas BJ, et al. Minimally invasive local therapies for liver cancer[J]. Cancer Biol Med, 2014, 11(4): 217-36. https://www.researchgate.net/publication/271331685_Minimally_invasive_local_therapies_for_liver_cancer
计量
- 文章访问数: 1678
- HTML全文浏览量: 355
- PDF下载量: 459
